Michael Andrew Chambers, Director at Sarepta Therapeutics, Inc. (SRPT), bought 69,734 shares at $104.67 ($7.4M) on 2023-08-10, disclosed to the SEC on 2023-08-11.
Open-market purchase of $7.4M SRPT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $104.67 | 2,206 | $231K | 3.1% |
| 2 | $104.67 | 2,206 | $231K | 3.1% |
| 3 | $105.90 | 1,091 | $116K | 1.6% |
| 4 | $105.90 | 1,091 | $116K | 1.6% |
| 5 | $106.26 | 31,570 | $3.4M | 45.3% |
| 6 | $106.26 | 31,570 |
| $3.4M |
| 45.3% |
| Total | $106.15 avg | 69,734 | $7.4M | 100% |
| Filing → |
| SRPT | BUY | 2023-08-14 | $5.1M | — | Filing → |
| SRPT | BUY | 2022-09-15 | $11.3M | — | Filing → |
| SRPT | BUY | 2022-08-22 | $5.0M | — | Filing → |